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Obesity is a risk factor for primary graft dysfunction (PGD), a form of lung injury resulting from ischemiareperfusion after lung transplantation, but the impact of ischemia-reperfusion on adipose tissue is unknown. We evaluated differential gene expression in thoracic visceral adipose tissue (VAT) before and after lung reperfusion. Total RNA was isolated from thoracic VAT sampled from six subjects enrolled in the Lung Transplant Body Composition study before and after allograft reperfusion and quantified using the Human Gene 2.0 ST array. Kyoto Encyclopedia of Genes and Genomes pathway analysis revealed enrichment for genes involved in complement and coagulation cascades and Jak-STAT signaling pathways. Overall, 72 genes were upregulated and 56 genes were downregulated in the postreperfusion time compared with baseline. Long pentraxin-3, a gene and plasma protein previously associated with PGD, was the most upregulated gene (19.5-fold increase, p = 0.04). Fibronectin leucine-rich transmembrane protein-3, a gene associated with cell adhesion and receptor signaling, was the most downregulated gene (4.3-fold decrease, p = 0.04). Ischemia-reperfusion has a demonstrable impact on gene expression in visceral adipose tissue in our pilot study of nonobese, non-PGD lung transplant recipients. Future evaluation will focus on differential adipose tissue gene expression and the development of PGD after transplant.
Introduction
Lung transplantation is an established therapy for severe incurable lung diseases, such as chronic obstructive pulmonary disease, idiopathic pulmonary fibrosis, cystic fibrosis, and pulmonary hypertension. Obesity, as measured by the BMI, has been linked to increased risk of primary graft dysfunction (PGD), a form of lung injury resulting from ischemia-reperfusion after lung transplantation (1) . The impact of ischemia-reperfusion on adipose tissue at the time of lung transplantation is unknown.
Obesity is known to produce a chronic, systemic proinflammatory milieu that likely plays a role in the development of disease (2, 3) . Adipocytes have well-characterized endocrine functions and respond to inflammatory insults, including hypoxia and hypoxia-reoxygenation (H-R) (2) . Cultured mature human adipocytes exposed to H-R demonstrate higher gene expression levels of proinflammatory cytokines and genes, including inducible nitric oxide synthase, cyclooxygenase-2, IL-1b, vascular endothelial growth factor, heme oxygenase 1, and tumor necrosis factor alpha, than normoxic cells (4) . In mouse models of acute respiratory distress syndrome, obesity is associated with higher levels of leukocyte adhesion markers in pulmonary vasculature, as measured by gene and protein expression levels of intercellular adhesion molecule-1, vascular cell adhesion molecule, and E-selectin in lung endothelial cells, and enhanced susceptibility to lipopolysaccharide-induced lung injury (5) .
Despite the association of obesity with significant outcomes after lung transplantation, BMI remains a poor surrogate measure for adiposity. BMI, as well as other anthropometric indices, poorly predicts internal body fat compartments, specifically the visceral adipose compartment. BMI may in fact strongly underestimate the risk impact of adiposity on disease states (6) . In order to better understand the association of adiposity with outcomes after lung transplantation, we evaluated the changes in gene expression levels in thoracic visceral adipose tissue (VAT) associated with ischemia-reperfusion occurring at the time of lung transplantation.
Materials and Methods

Participant selection and cohort design
Subjects were enrolled from the prospective, multicenter Lung Transplant Body Composition Study cohort study between 2013 and 2014. The institutional review boards of each site approved the study and all participants provided written informed consent. Clinical data on all study subjects were collected prospectively.
Adipose tissue sampling and gene expression analysis
Approximately 5 g of adipose tissue was removed from mediastinal structures at two time points: during initial dissection and following reperfusion of the allograft. Tissue was immediately placed in phosphatebuffered saline and then cut into 3-mm cubes. Following centrifugation at 500g for 5 min, tissue was placed in ALLprotect (Qiagen, Hilden, Germany) and stored at À20°C. Additional tissue was snap frozen and stored in liquid nitrogen. Total RNA was isolated from thoracic VAT using Qiagen's RNeasy Mini Kit (Qiagen, Hilden, Germany). A spectrophotometer was used to measure purity and concentration of isolated RNA. RNA expression was quantified using the Human Gene 2.0 ST array (Affymetrix, Santa Clara, CA).
Statistical analysis
Affymetrix GeneChip Human Gene 2.0 ST CEL files were normalized to produce gene-level expression values using the implementation of the Robust Multiarray Average in the affy package (version 1.36.1) included within the Bioconductor software suite (version 2.12) and an Entrez Gene-specific probeset mapping (version 16.0.0) from the Molecular and Behavioral Neuroscience Institute (Brainarray) at the University of Michigan (7) (8) (9) (10) (11) . Array quality was assessed by computing Relative Log Expression and Normalized Unscaled Standard Error using the affyPLM Bioconductor package (version 1.34.0) (12) . Principal component analysis was performed using the prcomp R function with expression values that had been normalized across all samples to a mean of zero and a standard deviation of 1. Linear fold changes were computed in a paired manner for the whole-tissue analyses (i.e. the mean of the ratios of 2 log2(expression) computed within each patient between time points). These fold changes were converted to a signed metric by taking the negative reciprocal of any fold changes less than 1. Linear mixed-effects modeling and the associated analyses of variance were carried out using the lme and anova.lme functions, respectively, in the nlme package (version 3.1-108). Paired or unpaired Student t-tests were computed using the limma package (version 3.14.4) by creating simple linear models with lmFit (with or without adjustment for patient, respectively), and performing t-tests on the time point model coefficient of each model. Correction for multiple hypothesis testing was accomplished using the Benjamini-Hochberg false discovery rate (FDR) (13) . A FDR-corrected p-value <0.05 was utilized to assess significance. All microarray analyses were performed using the R environment for statistical computing (version 2.15.1) (14, 15) . Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis was performed using Gene Annotation Tool to Help Explain Relationships utilizing inferences from networks (16) . Pathways with p > 0.05 and Bayes factor ≥6 were considered statistically significantly enriched.
Results
Due to the small number of patients with adipose tissue sample available both before and after allograft reperfusion and the low rate of PGD among those patients, for this pilot study we restricted analysis to patients without PGD at 72 h after transplant who had pre-and postreperfusion samples available. Paired before and after reperfusion thoracic VAT samples were available for six patients and were assessed for differential gene expression. Clinical characteristics of those patients are presented in Table 1 . Of note, the mean BMI of study subjects was 23.6 kg/m 2 . In the six paired thoracic VAT samples, there were a total of 128 genes differentially expressed pre-and postallograft reperfusion. Of those genes, 72 were upregulated in the postreperfusion samples compared with the prereperfusion tissue ( Table 2) . 46 of these genes (64%) had a fold increase ≥1.5. The single most upregulated gene was long pentraxin-3 (PTX3), a secreted innate immune acute phase reactant (19.5 fold There were 56 genes significantly downregulated in the postreperfusion samples compared with the prereperfusion thoracic VAT biopsies (Table 3) . Twenty-five of these genes (45%) had a fold increase ≥1.5. The most downregulated gene was fibronectin leucine-rich transmembrane protein-3 (FLRT3) (À4.3 fold change, FDR p = 0.04). FLRTs are involved in cell adhesion and Finally, we sought to understand which pathways were overrepresented by the differentially expressed gene expression patterns identified. KEGG pathway analysis on the differentially expressed genes with fold change ≥|1.5| revealed enrichment for genes involved in complement and coagulation cascades and Jak-STAT signaling pathways (Table 4) .
Discussion
In a small pilot study of six lung transplant recipients without PGD, we identified 128 genes that were differentially expressed in thoracic VAT following lung allograft reperfusion compared to thoracic VAT obtained prior to transplantation, highlighting the impact of ischemia reperfusion on thoracic VAT. The most differentially expressed gene in this small sample was PTX3, which has been previously implicated in the development of PGD (17, 18) . Obesity is a well-defined risk factor for both mortality and PGD after lung transplantation. While this study included normal-weight subjects, the changes in gene expression we observed directly in visceral adipose tissue suggest that changes occurring in thoracic VAT during surgery might contribute to lung inflammation and/or injury. Additionally, in a study of potential lung transplant candidates, 62% of obese/sarcopenic subjects, as determined by whole-body dual x-ray absorptiometry, had a normal BMI, highlighting both the limitation of BMI for the assessment of adiposity and the need for studies focused on direct evaluation of adiposity (20) .
Our pathway analysis indicated that complement and coagulation cascade pathways were the most overrepresented among genes differentially expressed in thoracic VAT in the setting of lung transplantation. Plasma differences in proteins involved in these pathways have been associated with PGD risk after lung transplantation in prior studies (21, 22) . Circulating levels of the anticoagulant protein C are lower in those with PGD compared to those without PGD, while levels of the pro-inflammatory protein plasminogen activator inhibitor-1 (PAI-1) are higher in those with PGD (21) . Changes in plasma levels of complement protein 5a, a potent neutrophil and lymphocyte chemoattractant, are associated with PGD after transplant (22) . Plasma levels of these proteins are also Genes with significantly downregulated gene expression in thoracic adipose tissue after lung reperfusion compared with prior to reperfusion. excellent predictors of obesity, with PAI-1 being one of the top five circulating biochemical predictors of total, abdominal, visceral, and liver fat (23) . Plasma PAI-1 activity is strongly correlated with elevated plasma triglyceride levels while plasma levels of complement protein 3a increase with increasing level of obesity (24, 25) . Given the separate association of coagulation and complement abnormalities with both adiposity and PGD after transplant, dysregulation of these pathways in thoracic VAT is an intriguing potential mechanism for the association of adiposity with PGD after lung transplantation.
PTX3 is highly evolutionarily conserved and plays a central role in innate immune responses, host defense, response to ischemia-reperfusion injury, and activation and modulation of the complement cascade. PTX3 was the most upregulated gene in thoracic VAT in the setting of lung allograft reperfusion, further highlighting the finding of complement pathway overrepresentation in this study. We have previously demonstrated that genetic variation in PTX3 is significantly associated with risk of PGD after lung transplantation and that increased plasma protein levels of PTX were associated with increased risk of PGD, predominantly among subjects transplanted for interstitial lung disease (17, 18) . PTX3 is also associated with obesity, with higher plasma levels found in obese adults with BMI >40 and obese children with obstructive sleep apnea compared to normal-weight subjects (26, 27) . Identification of increased PTX3 gene expression in the thoracic VAT of non-PGD, nonobese patients with lung reperfusion provides further credence to a systemic, recipient innate immune response to ischemiareperfusion injury in the setting of lung transplantation. Given the role of PTX3 in the pathogenesis of PGD, its association with obesity, and the observation that visceral adipose tissue gene expression of PTX3 significantly increases in the setting of ischemia-reperfusion in the absence of clinically apparent PGD, future investigation should focus on the potential mechanistic role of PTX3 in the link between obesity and PGD as well as an evaluation of the association between obesity and circulating plasma PTX3 levels.
FLRT3, the most downregulated gene in thoracic VAT, encodes a protein involved in cell adhesion and adipocytokine signaling pathways (19) . FLRT3 was reported to be differentially expressed in omental fat compared to subcutaneous adipose tissue, although the functional implications of this are not well defined (28) . Future evaluation should focus on the potential impact of ischemiareperfusion injury on the integrity of adipose cell-cell interactions and adipocyte signaling.
There are limitations to our study. As the total number of patients available for study is small, we chose to focus on a homogeneous sample, limiting the analysis to nonobese single lung transplant recipients without PGD after lung transplantation. Conclusions made using this population cannot be directly applied to an obese population or to patients with PGD. While the patients included in this study were predominantly normal weight (mean BMI 23.6 kg/m 2 ), BMI is a poor surrogate for actual body composition (6) . One of the strengths of this study is the focus on gene expression directly from thoracic visceral adipose tissue rather than a reliance on anthropometric measures of body composition. While the current study focuses only on non-PGD patients, we can conclude that ischemiareperfusion has a significant impact on visceral adipose tissue gene expression in lung transplant recipients. One resulting hypothesis is that the volume or amount of visceral adipose tissue present in the thorax of transplant recipients may lead to a dose-response relationship with PGD risk. Future studies identifying potential causal mediators for the relationship between adiposity and poor outcomes after transplant and on the impact of more significant adiposity on PGD risk mediated via gene expression differences is an area of ongoing focus. While the sample size is small, similarities in genes and pathways identified in this study compared with previous studies add to the validity of our findings. Due to the small amount of thoracic VAT initially procured and the lack of sufficient residual RNA, quantitative polymerase chain reaction was not performed for technical replication of the identified microarray gene expression differences. While we are unable to provide technical replication, the similarity of our findings with previous studies of lung transplant recipients, specifically the role of long PTX3 and complement and coagulation pathways, adds significant biological relevance to our findings.
In summary, ischemia-reperfusion at the time of lung transplant has a demonstrable impact on gene expression in visceral adipose tissue in our pilot study of nonobese, non-PGD lung transplant recipients, highlighted by the finding of PTX3 upregulation and coagulation and complement pathways overrepresentation in association with allograft reperfusion in lung transplant recipients. Future evaluation will focus on differential adipose tissue gene expression and the development of PGD. Differences in adipose tissue gene expression profiles may provide a link between recipient adiposity, PGD, and mortality risk after lung transplantation.
